You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Authors

  • Peter Kar Han Lau Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaMolecular Oncology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Breon Feran Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Lorey Smith Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Arian Lasocki Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, AustraliaDepartment of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Ramyar Molania Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Kortnye Smith Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Alison Weppler Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Christopher Angel Department of Histopathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Damien Kee Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaDepartment of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Prachi Bhave Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Belinda Lee Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Richard J Young Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Amir Iravani Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, AustraliaDepartment of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Hanxian Aw Yeang Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Ismael A Vergara Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaMelanoma Institute Australia, North Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • David Kok Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Kate Drummond Department of Neurosurgery, The Royal Melbourne Hospital, Melbourne, Victoria, AustraliaDepartment of Surgery, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Paul Joseph Neeson Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Karen E Sheppard Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Tony Papenfuss Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, AustraliaResearch Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Benjamin J Solomon Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Shahneen Sandhu Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Grant A McArthur Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Grant A McArthur; grant.mcarthur{at}petermac.org
View Full Text

Citation

Lau PKH, Feran B, Smith L, et al
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Journal for ImmunoTherapy of Cancer 2021;9:e002995. doi: 10.1136/jitc-2021-002995

Publication history

  • Accepted August 20, 2021
  • First published October 8, 2021.
Online issue publication 
June 27, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.